On Oct. 8, 2020, a clinical trial to test the safety, tolerability and efficacy of a combination treatment regimen for coronavirus disease 2019 (COVID-19) consisting of the antiviral remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, was begun. The study took place in hospitalized adults with COVID-19 in the U.S., Mexico and 16 other countries on five continents. The National Institute of Allergy and Infectious Diseases (NIAID) sponsored and funded the Phase 3 trial, called Inpatient Treatment with Anti-Coronavirus Immunoglobulin, or ITAC.